How Industry Collaborations Are Advancing Digital Biomarker Validation

Introduction: The Need for Cross-Industry Collaboration

Digital biomarkers offer exciting potential for continuous, patient-centric data in clinical trials. However, the path to regulatory acceptance is complex. Unlike traditional biomarkers, digital endpoints often rely on proprietary devices, algorithms, and decentralized capture models. To gain regulatory confidence, validation must be robust, multi-dimensional, and reproducible across populations, settings, and devices.

This has driven a rise in industry collaborations—including public-private consortia, academic alliances, and precompetitive initiatives. These partnerships allow sharing of data, standardization protocols, and regulatory engagement strategies to accelerate the qualification of digital biomarkers.

Why Biomarker Validation Demands Collaboration

No single sponsor can generate enough data to validate a digital biomarker across:

• Diverse patient populations
• Multiple device ecosystems
• Varying clinical environments
• Multiple endpoints and therapeutic contexts

Moreover, FDA and EMA often expect cross-study evidence. Sharing real-world and trial data across organizations enhances statistical power and generalizability, leading to stronger regulatory submissions.

Key Types of Industry Collaborations

• Consortia: Formal bodies uniting sponsors, CROs, tech vendors, and regulators (e.g., CTTI, DiMe)
• Precompetitive Research: Sharing algorithms and annotated datasets without commercial implications
• Joint Pilot Studies: Multi-sponsor studies collecting validation data for digital endpoints
• Academic Alliances: Partnerships with universities for access to subject matter expertise and independent data

These collaborations are often funded jointly and governed by steering committees or scientific advisory boards.

Case Study: Digital Medicine Society (DiMe) Collaboration

DiMe launched a multistakeholder project to validate sleep as a digital endpoint in depression trials. The collaboration included:

• Pharma companies (e.g., Pfizer, Janssen)
• Device makers (e.g., Fitbit)
• Academic institutions (e.g., Harvard)
• Regulatory observers (e.g., FDA reps)

The initiative produced an open-access Sleep Monitoring Toolkit and led to harmonized approaches for sleep-derived endpoints across trials.

Collaborative Data Repositories and Shared Standards

Data sharing underpins successful validation. Common repositories include:

• mPower Study (Parkinson’s): Shared voice and gait datasets for algorithm development
• All of Us Research Program: Offers wearable and EHR data to approved researchers
• CTTI’s Digital Trials Library: Contains digital endpoint study metadata across sponsors

These databases support benchmarking, replicate studies, and reduce duplication of efforts. For consistent structuring, CDISC has introduced SDTM modules for wearable-derived data.

Role of CROs in Facilitating Collaboration

Contract Research Organizations (CROs) often serve as the bridge between sponsors, technology vendors, and regulators. Their contributions include:

• Aggregating multisponsor datasets from decentralized trials
• Ensuring consistent metadata and audit trail compliance
• Maintaining centralized analytics pipelines
• Supporting real-time dashboarding and algorithm performance tracking

Some CROs even host joint digital biomarker working groups and facilitate early scientific advice meetings with authorities.

Regulatory Guidance Supporting Collaborative Validation

Regulatory agencies have increasingly encouraged industry-wide collaboration. Key documents include:

• FDA’s Qualification of Digital Health Technologies for Remote Data Acquisition: Highlights the role of consortia and multi-source evidence
• EMA’s Draft Guideline on Computerised Systems and Electronic Data: Suggests industry-wide governance frameworks for data collected remotely
• ICH E6(R3) Draft: Endorses use of real-world digital data for endpoint generation in trials

These frameworks signal that collaborative validation aligned with public standards may expedite regulatory qualification.

Governance Models in Biomarker Consortia

Effective collaboration requires robust governance models, including:

• Scientific Steering Committees: Set research direction and oversee study design
• IP and Data Use Agreements: Define ownership, access rights, and publication policies
• Ethics and Privacy Panels: Ensure regulatory compliance and patient protections
• Regulatory Advisory Boards: Maintain engagement with FDA/EMA throughout the process

Transparent operating models promote trust, participation, and long-term sustainability.

Multi-Sponsor Trials: Challenges and Best Practices

In joint studies involving multiple sponsors or device partners, common challenges include:

• Protocol harmonization across pipelines
• Device interoperability and calibration
• Variability in data annotation and labeling
• Data rights management for secondary analyses

Best practices to mitigate these issues:

• Use modular protocols with shared core elements
• Adopt FDA- or EMA-reviewed wearable platforms
• Define data dictionaries and use CDISC-aligned formats
• Include all stakeholders in governance from Day 1

Future Trends in Biomarker Validation Partnerships

As digital biomarkers mature, the next wave of collaboration will focus on:

• Open-source algorithm benchmarking: Standard libraries with peer-reviewed performance
• Virtual sandboxes: Testing environments for new endpoints with simulated data
• Blockchain audit trails: Verifiable multi-party data lineage and validation records
• Global cloud platforms: Centralized validation datasets accessible under secure frameworks

These efforts aim to shift from siloed innovation to interoperable, validated digital biomarkers embedded in every major clinical pipeline.

Real-World Collaboration Snapshot: The Mobilise-D Project

The Mobilise-D consortium, funded by the European IMI program, unites 34 partners across pharma, academia, and SMEs to develop digital mobility outcomes in chronic disease. Key takeaways:

• Use of standard gait sensors across trials
• Establishment of reference datasets and analytical algorithms
• Regulatory consultation from project inception
• Development of endpoints applicable to Parkinson’s, COPD, and MS

Such models are already reshaping how regulators assess digital endpoints in Europe.

Conclusion: The Future is Collaborative

Digital biomarker validation cannot be achieved in isolation. It requires shared evidence, joint pilots, aligned protocols, and collective engagement with regulators. Sponsors, CROs, tech vendors, and academic partners each play a vital role in establishing robust, validated, and accepted digital endpoints.

As regulators evolve frameworks for digital health, collaborative models will define the gold standard for evidence generation. Proactive participation in consortia and shared initiatives is not only a strategic advantage—it’s essential for driving innovation and patient benefit.

How to Validate Wearable Devices for Use as Clinical Endpoints

Why Validation of Wearables is Critical in Clinical Trials

As wearables become central to data capture in modern clinical trials, validating them for endpoint measurement is no longer optional—it is essential. Regulatory agencies like the FDA, EMA, and ICH stress that any device used to support a clinical endpoint must undergo a fit-for-purpose validation process. This ensures the data collected is reliable, reproducible, and acceptable for submission.

In the context of ICH E6(R3), wearable devices are considered computerized systems contributing to clinical data. Therefore, they must meet validation requirements aligned with GxP principles, including ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available).

For example, in a Phase II Parkinson’s study using gait monitoring sensors as a primary endpoint, the sponsor faced delays due to inadequate validation data. Rework required a complete re-submission of protocol amendments. This underlines the need for methodical planning from the outset.

Types of Clinical Endpoints Supported by Wearables

The type of endpoint intended for regulatory submission determines the validation strategy. Wearables can support a wide range of endpoints:

• Primary Endpoints: e.g., mean heart rate over 24 hours, gait speed in m/s
• Secondary Endpoints: sleep duration, step count, respiratory rate
• Exploratory Endpoints: voice biomarkers, posture shifts, tremor intensity

The higher the regulatory weight of the endpoint (e.g., primary vs exploratory), the more stringent the validation requirements. Primary endpoints require device accuracy, specificity, and precision to be statistically verified against gold-standard comparators.

Below is a dummy table outlining validation targets for common endpoint types:

Regulatory Expectations for Wearable Validation

According to the FDA’s Digital Health Technologies guidance (2023), sponsors must:

• Define how the wearable-derived measurement reflects the clinical concept of interest
• Show that the device consistently produces reliable data under field conditions
• Demonstrate analytical and clinical validity, especially for primary endpoints
• Control device versioning and firmware to prevent variability
• Submit source validation reports in IND or NDA submissions

The EMA similarly requires sponsors to perform performance evaluation under GCP conditions. Sponsors are encouraged to engage in Scientific Advice Meetings (SAM) or pre-IND discussions to align on validation requirements.

Analytical Validation of Wearable Metrics

Analytical validation confirms that a wearable accurately and consistently measures the intended physiological signal. This is typically done by comparing data from the wearable to a gold-standard method under controlled conditions.

• Accuracy: Degree of agreement with comparator
• Precision: Repeatability across multiple readings
• Linearity: Proportionality across different ranges
• Drift: Signal stability over time

Example: For a wearable measuring heart rate, validation would involve side-by-side readings with a medical-grade ECG at multiple time points, activities (rest, walking), and subjects.

Statistical tests like Bland-Altman plots, Pearson correlation, and RMSE (Root Mean Square Error) are used to evaluate analytical performance. Acceptance criteria must be pre-defined in the protocol and SAP.

Clinical Validation in Real-World Settings

After analytical validation, wearables must undergo field testing to confirm performance in actual trial settings. This assesses:

• Data Completeness: Percent of usable data collected
• Device Usability: Patient adherence and comfort
• Environmental Interference: Signal distortion from noise, temperature, humidity
• Connectivity Reliability: Sync success rates, dropout recovery

In a pilot study for a wearable respiratory sensor, data loss due to poor Bluetooth pairing occurred in 18% of participants. This led to SOP updates and a new training module for study coordinators.

Clinical validation can be performed in a sub-study, typically Phase I or II, prior to full-scale deployment in pivotal trials. Documentation must include protocol, consent forms, raw data, and performance summary.

Documenting Validation for Regulatory Submission

All validation efforts must be captured in a traceable, review-ready format. A typical validation file includes:

• Validation Master Plan (VMP)
• Test Scripts and Reports
• Version Control Log for firmware/software
• Vendor Qualification Dossier
• Clinical Summary Table

These documents support submission in eCTD Module 5 or during site inspections. Sponsors should also include mitigation plans for known device limitations, such as alternate procedures for device loss or failure.

Sponsors may also generate a Device Data Specification Sheet outlining:

• Sample rate and resolution
• Data storage and transfer architecture
• Timestamp behavior (e.g., UTC sync)

CAPA and Change Control for Device Updates

During long trials, wearable devices may require firmware updates or supplier changes. All changes must follow formal change control and be assessed for validation impact.

Corrective and Preventive Actions (CAPA) may be triggered by:

• Unexpected data discrepancies or dropout rates
• Field complaints from sites or patients
• New regulatory guidance or audit findings

For instance, in a dermatology trial, a firmware update introduced timestamp rounding errors. CAPA investigation revealed the root cause and required deployment rollback across 40 sites.

Such changes must be documented in the TMF and included in the validation report addendum.

Conclusion: From Wearable to Validated Endpoint

Validating wearables for clinical endpoints ensures trust in the data generated and regulatory acceptance of trial outcomes. From initial analytical testing to real-world clinical validation and submission documentation, each step must be handled with scientific rigor and regulatory discipline.

As digital health evolves, wearable validation will play a defining role in enabling decentralized, real-time, patient-centric trials. CROs and sponsors that embed validation early and systematically into trial planning will not only reduce delays but also future-proof their study operations.